BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of over 1000 found
  Current Search:  clinic: 21844, phase: 8892, trial: 14373     

HTML
100%
Xenoport, Inc. Q1 2008 Earnings Call Transcript
Katherine Xu - Credit Suisse Juan Sanchez - Ladenburg Thalmann Presentation Operator Good afternoon.

My name is Christine, and I will be your conference operator today.

At this time, I would like to welcome everyone to the XenoPort first...

Yahoo!:  May 14 2008 3:13AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Amicus Therapeutics Inc. Q1 2008 Earnings Call Transcript
Let me begin by saying that as many of you know, Amicus Therapeutics is a bio-pharmaceutical company and that we focus on developing small molecule drugs, known as pharmacological chaperones for the treatment of a broad range of human...
Yahoo!:  May 14 2008 3:12AM
Matching: clinic phase trial
Find similar documents
HTML
100%
ThromboGenics N.V. - Business Update
- Regulated Information ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for vascular disease, eye disease and cancer, is today issuing a business update for the three month period ended 31...
DiGiTAL50:  May 14 2008 9:20AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

('Oncolytics') TSX:ONC ONCY announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Houston Chronicle:  May 14 2008 6:54AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating
CALGARY, Canada, May 14 /PRNewswire/ -- Oncolytics Biotech Inc.

(News) ('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency...

FinanzNachrichten.de:  May 14 2008 6:42AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA...

Genetic Engineering News:  May 14 2008 6:36AM
Matching: clinic phase trial
Find similar documents
HTML
100%
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign
QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.

(NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the...

Forbes.com:  May 14 2008 12:06PM
Matching: clinic phase trial
Find similar documents
HTML
100%
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase
QUEBEC CITY, May 14 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc.

(News) (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of...

FinanzNachrichten.de:  May 14 2008 12:02PM
Matching: clinic phase trial
Find similar documents
HTML
100%
terna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign P
QUEBEC CITY, May 14 /CNW Telbec/ - terna Zentaris Inc.

(NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the Company's ...

Macro World Investor:  May 14 2008 12:02PM
Matching: clinic phase trial
Find similar documents
HTML
100%
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign
QUEBEC CITY, May 14 /CNW Telbec/ - AEterna Zentaris Inc.

(NASDAQ: AEZS - News; TSX: AEZ - News), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the...

Yahoo! Canada:  May 14 2008 11:49AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Molecular Insight Pharmaceuticals, Inc.

(NASDAQ: MIPI) announced today financial results for the quarter ended March 31, 2008 and reiterated its clinical guidance for fiscal year 2008.

'During the first quarter, Molecular Insight...

Forbes.com:  May 14 2008 1:07PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of
- Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3 treatment-experienced patients - Pharmasset, (News) Inc.

(Nasdaq: VRUS) has commenced dosing two...

FinanzNachrichten.de:  May 14 2008 11:15AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
, 8:30 AM EST News source: Business Wire Molecular Insight Pharmaceuticals, Inc.

(NASDAQ: MIPI) announced today financial results for the quarter ended March 31, 2008 and reiterated its clinical guidance for fiscal year 2008.

...

Genetic Engineering News:  May 14 2008 1:10PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
CAMBRIDGE, Mass.

- (Business Wire) Molecular Insight Pharmaceuticals, Inc.

(NASDAQ: MIPI) announced today financial results for the quarter ended March 31, 2008 and reiterated its clinical guidance for fiscal year 2008.

During...

Earthtimes.org:  May 14 2008 1:03PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Size: Print Jazz Pharmaceuticals, Inc.

(JAZZ) Q1 2008 Earnings Call Executives Matt Fust - CFO Sam Saks - CEO Bob Myers - President Analysts Rich Silver - Lehman Brothers Marc Goodman - Credit Suisse Corey Davis - Natexis Presentation...

Yahoo!:  May 14 2008 3:13AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial...
Yahoo!:  May 14 2008 10:47AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (News) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial in combination...
FinanzNachrichten.de:  May 14 2008 10:39AM
Matching: clinic phase trial
Find similar documents
HTML
100%
/R E P E A T -- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Co
CALGARY, May 14 /CNW/ - Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Canada NewsWire:  May 14 2008 1:05PM
Matching: clinic phase trial
Find similar documents
HTML
100%
/R E P E A T -- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Co
CALGARY, May 14 /CNW/ - Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Canadian Business Magazine:  May 14 2008 12:57PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination With P
CALGARY, May 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency ...

Red Orbit:  May 14 2008 11:34AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a ...

TradingMarkets:  May 14 2008 9:18AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
CALGARY, May 14 /CNW/ - Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Yahoo! Canada:  May 14 2008 7:28AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA...

Macro World Investor:  May 14 2008 6:52AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

('Oncolytics') announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical...

Stockwatch:  May 14 2008 6:40AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with P
CALGARY, May 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.

('Oncolytics') (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K.

Medicines and Healthcare products Regulatory Agency ...

Advanced Financial Network:  May 14 2008 6:26AM
Matching: clinic phase trial
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.